# Angina Market

> Angina Market Research Report, by Type (Angina Pectoris), Diagnosis (Imaging, Stress Test), Treatment (Lifestyle, Medications, Angioplasty, and Stenting), End-Users (Hospital & Clinics, Diagnostic Centers, Academic Institutes)–Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.52%
- **2024:** $ 0.55 Billion
- **2025:** $ 0.58 Billion
- **2035:** $ 0.99 Billion
- **Key Players:** AstraZeneca (GB), Bristol-Myers Squibb (US), Novartis (CH), Pfizer (US), Sanofi (FR), Merck & Co. (US), GlaxoSmithKline (GB), Amgen (US), Bayer (DE)

**Report ID:** MRFR/Pharma/4293-HCR · **Pages:** 90 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** May 13, 2026

**URL:** https://www.marketresearchfuture.com/reports/angina-market-5748

---

## Market Summary

As per Market Research Future analysis, The Global Angina Market Size was estimated at 0.5487 USD Billion in 2024. The Angina industry is projected to grow from 0.579 USD Billion in 2025 to 0.9909 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.52% during the forecast period 2025 - 2035

## Market Drivers

### Advancements in Medical Technology

Technological innovations in medical devices and treatment methodologies are transforming The Global Angina Industry. The introduction of minimally invasive procedures, such as percutaneous coronary interventions, has revolutionized the management of angina. These advancements not only enhance patient outcomes but also reduce recovery times, making treatments more appealing to patients and healthcare providers alike. Additionally, the development of advanced diagnostic tools, such as high-resolution imaging techniques, allows for earlier detection and more personalized treatment plans. As these technologies become more widely adopted, they are expected to drive market growth by improving the efficacy of angina management. The integration of telemedicine and digital health solutions further supports this trend, enabling remote monitoring and management of patients, which could lead to increased adherence to treatment protocols and better overall health outcomes in The Global Angina Industry.

### Growing Focus on Preventive Healthcare

The shift towards preventive healthcare is significantly impacting The Global Angina Industry. As awareness of heart health increases, individuals are more inclined to seek preventive measures to mitigate the risk of developing angina and other cardiovascular conditions. This trend is reflected in the rising demand for screening programs, lifestyle modification initiatives, and educational campaigns aimed at promoting heart health. Healthcare providers are increasingly emphasizing the importance of early intervention and risk factor management, which could lead to a decrease in the incidence of angina. Consequently, this proactive approach may result in a more informed patient population that actively engages in their health, thereby driving the demand for preventive therapies and interventions within The Global Angina Industry.

### Regulatory Support for Innovative Therapies

Regulatory bodies are playing a pivotal role in shaping The Global Angina Industry by providing support for the development and approval of innovative therapies. Streamlined approval processes for new drugs and treatment modalities encourage pharmaceutical companies to invest in research and development. This regulatory environment fosters innovation, leading to the introduction of novel therapies that can effectively address the needs of angina patients. Additionally, incentives for the development of orphan drugs and therapies targeting specific patient populations may further stimulate market growth. As regulatory frameworks evolve to support advancements in treatment options, The Global Angina Industry is likely to experience an influx of new products, enhancing the overall landscape of angina management.

### Rising Prevalence of Cardiovascular Diseases

The increasing incidence of cardiovascular diseases is a primary driver for The Global Angina Industry. As lifestyle-related factors such as poor diet, lack of physical activity, and high stress levels contribute to heart conditions, the demand for effective angina treatments rises. According to health statistics, cardiovascular diseases account for a significant portion of global mortality, prompting healthcare systems to prioritize management strategies. This trend is likely to bolster the market for angina therapies, as patients seek interventions to alleviate symptoms and improve quality of life. Furthermore, the growing burden of these diseases necessitates innovative treatment options, thereby stimulating research and development in the pharmaceutical sector. Consequently, The Global Angina Industry is poised for growth as healthcare providers focus on addressing the needs of an increasingly affected population.

### Increased Investment in Healthcare Infrastructure

Investment in healthcare infrastructure is a crucial factor influencing The Global Angina Industry. Governments and private entities are increasingly allocating resources to enhance healthcare facilities, particularly in regions with high rates of cardiovascular diseases. This investment often translates into improved access to diagnostic and treatment services for angina patients. Enhanced healthcare infrastructure facilitates the availability of advanced treatment options, which can lead to better patient outcomes and increased demand for angina therapies. Moreover, the establishment of specialized cardiac care centers is likely to provide comprehensive management for patients suffering from angina, further driving market growth. As healthcare systems evolve and expand, The Global Angina Industry stands to benefit from the increased accessibility and quality of care provided to patients.

## Future Outlook

The Global Angina Market is projected to grow at a 5.52% CAGR from 2025 to 2035, driven by increasing prevalence, advancements in treatment options, and rising healthcare expenditure.

**New opportunities:**

- Development of telehealth platforms for remote patient monitoring. Investment in AI-driven diagnostic tools for early angina detection. Expansion of personalized medicine approaches targeting angina management.

By 2035, The Global Angina Market is expected to achieve substantial growth, reflecting evolving healthcare dynamics.

## Segment Insights

### By Type: Angina Pectoris (Largest) vs. Unstable Angina (Fastest-Growing)

In The Global Angina, angina pectoris holds the largest share, representing a significant portion of total cases. Unstable angina, while smaller in market share, is emerging as a critical focus due to its acute nature and potential for increased hospitalization and emergency intervention. Other types, including prinzmetal angina and miscellaneous cases, contribute to the market but do so at a lesser extent than the more prevalent forms of angina. Growth trends indicate that the population's aging demographics, along with rising levels of cardiovascular diseases, drive the demand for effective management of angina conditions. The increased awareness of heart-related issues and advancements in medical treatment options further amplify the interest and investment in addressing unstable angina, which has been identified as a rapidly growing area in the market.

Angina Pectoris (Dominant) vs. Prinzmetal Angina (Emerging)

Angina pectoris is characterized by chest pain resulting from reduced blood flow to the heart, making it the dominant type in The Global Angina due to its prevalence and straightforward recognition. Meanwhile, prinzmetal angina is considered emerging as it presents a unique pattern of chest pain related to coronary artery spasm rather than physical exertion. The unique characteristics of prinzmetal angina—often occurring at rest and associated with specific triggers—make it both a critical area for research and a unique challenge for treatment. As clinicians increasingly seek to understand and address this type of angina, it may gain more prominence in the market, influencing therapeutic innovation and expanding patient management options.

### By Diagnosis: Imaging (Largest) vs. Blood Test (Fastest-Growing)

In The Global Angina Market, the diagnosis segment is primarily driven by imaging, which holds the largest market share due to its effectiveness in visualizing anatomical structures and diagnosing conditions. Imaging techniques such as echocardiography and angiography are widely adopted for their precision and reliability, making them the preferred choice among healthcare professionals. Blood tests, though currently smaller in market share, are rapidly gaining traction as advancements in biomarkers and technologies emerge, enhancing their diagnostic capabilities. The growth trends in the diagnosis segment indicate a broader shift towards non-invasive and efficient diagnostic methods. The rise in healthcare awareness, combined with an increase in case prevalence, is driving the adoption of innovative diagnostic technologies. Additionally, the growing emphasis on early detection and personalized treatment plans is propelling the adoption of blood tests, which are seen as complementary to traditional imaging methods. Overall, this segment is witnessing dynamic changes, with emerging technologies reshaping diagnostic protocols and practices.

Imaging (Dominant) vs. Stress Test (Emerging)

In the context of The Global Angina Market, imaging stands as a dominant diagnostic tool primarily due to its ability to provide detailed anatomical views of cardiac structures. This method includes techniques like echocardiograms and coronary angiography, which are integral in evaluating blood flow and detecting blockages. The accuracy and reliability of imaging have solidified its place in standard clinical protocols, addressing a wide array of cardiac conditions effectively. On the other hand, stress tests, categorized as emerging diagnostic solutions, are gaining popularity for their role in assessing cardiac function under physical exertion. Although currently less prevalent than imaging, they are increasingly recognized for their value in comprehensive cardiovascular assessments, especially in scenarios where patients present atypical symptoms or need to gauge the efficacy of ongoing treatments.

### By Treatment: Medications (Largest) vs. Angioplasty and Stenting (Fastest-Growing)

In The Global Angina Market, the treatment segment exhibits a diverse distribution, with medications holding the largest share. This includes a broad category of pharmaceuticals that aid in managing angina symptoms effectively. Following medications, angioplasty and stenting have emerged as a rapidly growing segment, reflecting advances in minimally invasive procedures that enhance patient outcomes. Other segments such as lifestyle changes, coronary bypass surgery, and others contribute to the market, although their shares are comparatively smaller. The growth trends within this segment are primarily driven by increasing prevalence of cardiovascular diseases and a growing geriatric population. Innovations in drug formulations and techniques in interventional cardiology, like angioplasty and stenting, are also contributing factors. The shift towards preventive measures, including lifestyle changes, is further catalyzing market expansion, catering to the rising awareness of heart health and the demand for holistic treatment approaches.

Medications: Pharmacological Treatments (Dominant) vs. Angioplasty: Invasive Procedures (Emerging)

Medications are the cornerstone of treatment in The Global Angina Market, encompassing a range of pharmacological therapies aimed at alleviating chest pain and improving quality of life. These treatments include beta-blockers, nitrates, and calcium channel blockers, which have established efficacy in managing angina symptoms. Their dominance is attributed to their widespread availability and the established protocols governing their use in clinical settings. On the other hand, angioplasty and stenting are emerging as crucial alternatives in specific cases, providing a less invasive option that yields quick recovery and relief from symptoms. This segment is witnessing accelerated growth due to technological advancements and increasing patient preference for quicker interventions. Together, they represent a significant dichotomy in treatment approaches, with medications remaining the standard and angioplasty offering an innovative option.

### By End-User: Hospitals and Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing)

In The Global Angina Market, the primary distribution of market share among end-users reveals hospitals and clinics as the dominant segment, capturing a significant proportion of the market. This is due to their extensive resources, capability to provide comprehensive treatment options, and a well-established patient base. Following them, diagnostic centers are also emerging strongly as they play a crucial role in the early detection and timely diagnosis of angina, contributing to an evolving market landscape.

Hospitals and Clinics: Dominant vs. Diagnostic Centers: Emerging

Hospitals and clinics serve as the cornerstone of the healthcare infrastructure, offering specialized services for angina patients, including invasive procedures and ongoing management. Their established reputation and comprehensive care facilities ensure they remain the dominant end-user segment. Meanwhile, diagnostic centers, noted for their fast growth, provide essential diagnostic services that enhance early detection rates of angina, thereby increasing patient turnaround time for treatment. While hospitals focus on advanced treatment, diagnostic centers are pivotal in patient management pathways, showcasing complementary roles that enhance the overall healthcare delivery system.

## Regional Market Share Analysis

### North America : Healthcare Innovation Leader

North America is the largest market for angina treatments, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high disposable incomes, and a growing aging population, which drives demand for effective angina therapies. Regulatory support from agencies like the FDA further catalyzes market growth by expediting the approval of new drugs and therapies. The United States and Canada are the leading countries in this region, with major pharmaceutical companies like Pfizer, Merck & Co., and Bristol-Myers Squibb actively involved in developing innovative treatments. The competitive landscape is characterized by a mix of established players and emerging biotech firms, all striving to capture market share through research and development initiatives.

### Europe : Regulatory Framework Strength

Europe is the second-largest market for angina treatments, accounting for about 30% of the global market share. The region's growth is driven by increasing healthcare expenditure, a rise in cardiovascular diseases, and supportive regulatory frameworks. The European Medicines Agency (EMA) plays a crucial role in facilitating the approval of new therapies, which enhances market accessibility and patient care. Leading countries in Europe include Germany, France, and the United Kingdom, where key players like AstraZeneca and Novartis are heavily invested in research and development. The competitive landscape is robust, with numerous collaborations between pharmaceutical companies and research institutions aimed at advancing treatment options for angina patients.

### Asia-Pacific : Emerging Market Potential

Asia-Pacific is witnessing rapid growth in the angina market, holding approximately 20% of the global market share. Factors such as increasing urbanization, rising disposable incomes, and a growing prevalence of lifestyle-related diseases are driving demand for angina treatments. Governments in the region are also implementing healthcare reforms to improve access to medical services, which is expected to further boost market growth. Countries like China and India are at the forefront of this growth, with a significant presence of both local and international pharmaceutical companies. The competitive landscape is evolving, with key players like Sanofi and Bayer expanding their operations to cater to the increasing demand for effective angina therapies in these emerging markets.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region represents a smaller segment of The Global Angina Market, accounting for about 5% of the total market share. However, the region is characterized by untapped opportunities due to increasing healthcare investments and a rising burden of cardiovascular diseases. Governments are focusing on improving healthcare infrastructure, which is expected to drive demand for angina treatments in the coming years. Leading countries in this region include South Africa and the UAE, where there is a growing presence of international pharmaceutical companies. The competitive landscape is gradually evolving, with key players like Amgen and GlaxoSmithKline looking to expand their footprint in this region, capitalizing on the increasing healthcare needs of the population.

## Competitive Benchmarking

The Global Angina is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as AstraZeneca (GB), Novartis (CH), and Pfizer (US) are actively engaged in enhancing their product portfolios and expanding their market reach. AstraZeneca (GB) has positioned itself as a leader in cardiovascular therapies, emphasizing research and development to introduce novel treatments. Meanwhile, Novartis (CH) is focusing on strategic collaborations to enhance its drug pipeline, particularly in the realm of angina management. Pfizer (US) is leveraging its extensive distribution network to ensure that its angina therapies are accessible globally, thereby reinforcing its market presence.
The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The Global Angina appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like AstraZeneca (GB) and Pfizer (US) suggests a trend towards consolidation, as these firms seek to enhance operational efficiencies and streamline their offerings.
In August 2025, AstraZeneca (GB) announced a strategic partnership with a leading telehealth provider to integrate digital health solutions into its angina treatment protocols. This move is likely to enhance patient engagement and adherence to therapy, thereby improving clinical outcomes. The integration of telehealth services aligns with the growing trend of digitalization in healthcare, positioning AstraZeneca (GB) favorably in a competitive market.
In September 2025, Novartis (CH) launched a new angina treatment that utilizes a novel mechanism of action, which could potentially redefine treatment paradigms. This innovation not only underscores Novartis's commitment to research but also reflects a broader industry trend towards developing targeted therapies that address unmet medical needs. The introduction of this treatment may enhance Novartis's competitive edge, particularly in markets with high demand for advanced cardiovascular solutions.
In October 2025, Pfizer (US) expanded its global distribution network by entering into a strategic alliance with regional distributors in Asia-Pacific. This initiative is expected to facilitate quicker access to its angina therapies in emerging markets, where the prevalence of cardiovascular diseases is rising. By enhancing its supply chain capabilities, Pfizer (US) is likely to strengthen its market position and respond more effectively to regional healthcare demands.
As of October 2025, the competitive trends in The Global Angina are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming pivotal in shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, the competitive differentiation in this market is expected to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and the reliability of supply chains. This shift may ultimately lead to improved patient outcomes and a more sustainable healthcare ecosystem.

## Report Scope

| MARKET SIZE 2024 | 0.5487(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.579(USD Billion) |
| MARKET SIZE 2035 | 0.9909(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.52% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | AstraZeneca (GB), Bristol-Myers Squibb (US), Novartis (CH), Pfizer (US), Sanofi (FR), Merck & Co. (US), GlaxoSmithKline (GB), Amgen (US), Bayer (DE) |
| Segments Covered | Type |
| Key Market Opportunities | Advancements in telemedicine and digital health solutions enhance patient management in The Global Angina. |
| Key Market Dynamics | Rising prevalence of cardiovascular diseases drives demand for innovative therapies and treatment options in the angina market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of The Global Angina as of 2024?**
A: The Global Angina was valued at 0.5487 USD Billion in 2024.

**Q: What is the projected market valuation for The Global Angina in 2035?**
A: The market is projected to reach a valuation of 0.9909 USD Billion by 2035.

**Q: What is the expected CAGR for The Global Angina during the forecast period 2025 - 2035?**
A: The expected CAGR for The Global Angina during the forecast period 2025 - 2035 is 5.52%.

**Q: Which companies are considered key players in The Global Angina?**
A: Key players in the market include AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, Sanofi, Merck & Co., GlaxoSmithKline, Amgen, and Bayer.

**Q: What are the main segments of The Global Angina?**
A: The main segments of the market include Type, Diagnosis, Treatment, and End-User.

**Q: How does the angina pectoris segment perform in terms of market valuation?**
A: The angina pectoris segment was valued at 0.2 USD Billion in 2024 and is expected to grow to 0.4 USD Billion by 2035.

**Q: What is the market valuation for the stress test segment in 2024?**
A: The stress test segment was valued at 0.2 USD Billion in 2024 and is projected to reach 0.3 USD Billion by 2035.

**Q: What treatment options are included in The Global Angina?**
A: Treatment options include lifestyle changes, medications, angioplasty and stenting, coronary bypass surgery, and others.

**Q: What is the projected growth for the hospitals and clinics segment by 2035?**
A: The hospitals and clinics segment is expected to grow from 0.2743 USD Billion in 2024 to 0.4904 USD Billion by 2035.

**Q: How does The Global Angina's performance compare across different end-users?**
A: The market performance varies, with hospitals and clinics leading, followed by diagnostic centers and academic institutes.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/angina-market-5748*